Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas increased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 10.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,440 shares of the company’s stock after acquiring an additional 2,556 shares during the period. Teacher Retirement System of Texas’ holdings in Vir Biotechnology were worth $194,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new stake in Vir Biotechnology during the 4th quarter worth about $60,000. PNC Financial Services Group Inc. lifted its holdings in shares of Vir Biotechnology by 31.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after buying an additional 1,999 shares during the period. KBC Group NV increased its holdings in shares of Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock valued at $66,000 after purchasing an additional 5,177 shares in the last quarter. CIBC Asset Management Inc acquired a new stake in shares of Vir Biotechnology during the 4th quarter valued at approximately $74,000. Finally, Captrust Financial Advisors purchased a new stake in shares of Vir Biotechnology during the 3rd quarter worth approximately $118,000. 65.32% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Vir Biotechnology

In other news, EVP Verneuil Vanina De sold 7,373 shares of the company’s stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the transaction, the executive vice president now owns 79,460 shares in the company, valued at approximately $726,264.40. This represents a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the transaction, the director now directly owns 1,312,391 shares of the company’s stock, valued at $16,431,135.32. This trade represents a 0.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,859 shares of company stock valued at $326,458. Insiders own 15.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on VIR shares. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research report on Friday, February 28th. Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. JPMorgan Chase & Co. raised their price target on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research note on Thursday, January 9th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a report on Thursday, February 27th. Finally, Leerink Partners raised their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and an average target price of $35.67.

Vir Biotechnology Stock Up 4.9 %

Shares of NASDAQ:VIR opened at $6.48 on Thursday. The company has a 50 day moving average of $8.56 and a two-hundred day moving average of $8.32. Vir Biotechnology, Inc. has a 52-week low of $6.08 and a 52-week high of $14.45. The company has a market capitalization of $888.69 million, a price-to-earnings ratio of -1.65 and a beta of 1.17.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm had revenue of $12.37 million for the quarter, compared to the consensus estimate of $8.14 million. On average, equities analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).